Physician profile

Mukul Gupta

Hematology & Oncology · Santa Barbara, CA

NPI 1295843738

$11,407.20

in general payments reported to CMS, 2019-2025

48 companies · $372 in 2025

The $372 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,559.70
Education$30.65

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Kite Pharma, INC. $5,947.36 2022
Emd Serono, INC. $1,723.81 2022-2025
Celgene Corporation $1,115.02 2019-2020
E.R. Squibb & Sons, L.L.C. $271.77 2019-2023 Opdivo
Abbvie INC. $230.62 2022-2024
Janssen Biotech, INC. $200.79 2019-2024 Tecvayli, Carvykti
Glaxosmithkline, LLC. $170.69 2020-2022
Pfizer INC. $141.23 2021-2025
Novartis Pharmaceuticals Corporation $136.02 2019-2025
Astrazeneca Pharmaceuticals LP $126.58 2019-2025 Calquence, Lynparza, Enhertu
Jazz Pharmaceuticals INC. $116.86 2023
Adaptive Biotechnologies Corporation $111.17 2024-2025 Clonoseq
Seagen INC. $105.71 2019-2023 Adcetris
Sumitomo Pharma America, INC. $105.58 2024 Orgovyx
Tesaro, INC. $97.69 2019
Show all 38 companies
CompanyGeneral paymentsYearsTop products
Genzyme Corporation $80.11 2019
Astellas Pharma US INC $76.64 2019-2024 Xtandi
Alexion Pharmaceuticals, INC. $76.62 2023-2024 Ultomiris
Incyte Corporation $64.27 2023-2024 Jakafi
Adc Therapeutics America, INC. $54.12 2021-2022
Beigene USA, INC. $52.79 2020
Agios Pharmaceuticals, INC. $41.70 2025 Pyrukynd
Lilly USA, LLC $36.09 2022
Portola Pharmaceuticals, LLC $32.18 2019
Merck Sharp & Dohme LLC $30.78 2019
Daiichi Sankyo INC. $29.06 2024 Enhertu
Rigel Pharmaceuticals, INC. $25.12 2019
Takeda Pharmaceuticals U.S.A., INC. $24.27 2024 Fruzaqla
Eusa Pharma (US) LLC $23.96 2019
Acrotech Biopharma INC. $22.54 2025 Ryzneuta
Genmab U.S., INC. $20.28 2024 Epkinly
Regeneron Healthcare Solutions, INC. $18.96 2023 Libtayo
Flowonix Medical Incorporated $18.83 2019
Melinta Therapeutics, LLC $17.92 2024 Orbactiv, Kimyrsa, Rezzayo
Welch Allyn $16.78 2021
Boehringer Ingelheim Pharmaceuticals, INC. $15.72 2019
Bayer Healthcare Pharmaceuticals INC. $15.11 2019
Karyopharm Therapeutics INC. $12.45 2020

10 companies reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$1,228.75 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Mukul Gupta

$11,407.20

in general payments reported 2019-2025

Years
2019-2025
Top company
Kite Pharma, INC.
Context
The $372 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).

https://glasscript.com/doctor/195191/mukul-gupta

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.